Frontiers Winter 2017
The Director's Perspective: Offering Research-Based Compassionate Care
Year three begins for the new James Cancer Hospital and Solove Research Institute
It’s hard to believe that two years have passed since we opened our transformational James Cancer Hospital and Solove Research Institute as the adult patient-care component of The Ohio State University Comprehensive Cancer Center (OSUCCC – James).
Easier to believe is how much this facility has helped us extend our global impact in research and compassionate care. The OSUCCC – James has become an international destination for cancer treatment; we have now served patients from all 88 Ohio counties, all 50 American states and 36 other countries.
More people from around the world are turning to us for help because of our groundbreaking research, which we translate into innovative cancer care and prevention strategies, some of which are featured in this new Frontiers.
Our cover story examines a statewide project that we launched a few years ago called the Ohio Colorectal Cancer Prevention Initiative, which established a 50-hospital network for screening colorectal cancer (CRC) patients and their at-risk relatives for Lynch syndrome, an inherited genetic condition that predisposes to CRC and other cancers. One outcome of the project is a study published in JAMA Oncology that used multigene sequencing to learn the prevalence of mutations linked to hereditary cancer syndromes in a large group of CRC patients diagnosed under age 50. The prevalence proved to be amazingly high—16 percent—and not always Lynch syndrome.
Another story describes the work of four OSUCCC – James research groups that are studying how cancer cells derive the energy they need for rapid growth and proliferation. Their work is identifying promising prognostic and predictive biomarkers and new therapeutic targets to enhance cancer therapy.
You can also read about new microsurgical techniques to prevent or relieve lymphedema, about the support services needed for the ever-growing population of cancer survivors and about a clinical trial for uveal melanoma. I hope you’ll find this issue interesting and informative.